Corcept Therapeutics Inc

Corcept Therapeutics is a commercial-stage biotechnology company focused on the discovery and development of medications that modulate the effects of the hormone cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company has discovered over 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept markets Korlym, the first FDA-approved medication for endogenous Cushing's syndrome (approved 2012), and Lifyorli (relacorilant), approved in March 2026 in combination with nab-paclitaxel as the first FDA-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. The company is conducting advanced clinical trials across Cushing's syndrome (relacorilant NDA resubmitted, PDUFA date December 2026), multiple solid tumor types (ovarian, endometrial, cervical, pancreatic, and prostate cancers), metabolic dysfunction-associated steatohepatitis (MASH, via miricorilant), and amyotrophic lateral sclerosis (ALS, via dazucorilant). Corcept's pipeline molecules include relacorilant, miricorilant, dazucorilant, and nenocorilant, each targeting the glucocorticoid receptor with distinct pharmacological profiles. Updated Jul 29, 2026